338 related articles for article (PubMed ID: 18759308)
1. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
[TBL] [Abstract][Full Text] [Related]
4. Pegloticase: a novel agent for treatment-refractory gout.
Shannon JA; Cole SW
Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
6. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
7. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K; Scheinfeld N
Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
[TBL] [Abstract][Full Text] [Related]
8. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
9. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
12. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
14. Pegloticase for chronic gout.
Anderson A; Singh JA
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
Johnson RJ; Choi HK; Yeo AE; Lipsky PE
Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
[TBL] [Abstract][Full Text] [Related]
16. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Khanna PP; Khanna D; Cutter G; Foster J; Melnick J; Jaafar S; Biggers S; Rahman AKMF; Kuo HC; Feese M; Kivitz A; King C; Shergy W; Kent J; Peloso PM; Danila MI; Saag KG
Arthritis Rheumatol; 2021 Aug; 73(8):1523-1532. PubMed ID: 33750034
[TBL] [Abstract][Full Text] [Related]
17. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Schumacher HR; Becker MA; Lloyd E; MacDonald PA; Lademacher C
Rheumatology (Oxford); 2009 Feb; 48(2):188-94. PubMed ID: 19141576
[TBL] [Abstract][Full Text] [Related]
19. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.
Bleyer AJ; Wright D; Alcorn H
Clin Nephrol; 2015 May; 83(5):286-92. PubMed ID: 25816806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
